Plain-English translation of NCT06850571 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 4 โ The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing two medications โ bevacizumab and aflibercept โ that are injected directly into the eye to treat a condition called diabetic maculopathy, which causes vision loss in people with diabetes. The study will compare how well each medication works and whether one is safer or more cost-effective than the other. You would receive one of these treatments as a monthly injection for three months.
Diabetic maculopathy is a serious complication of diabetes that can lead to permanent vision loss. While this medication has been used to treat this condition, doctors want to know which option works best and costs less, so they can give patients the best possible care.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You would visit the clinic once a month for three months. At each visit, you would receive an injection of the medication into your eye, and the doctors would perform simple tests to measure your vision, check the thickness of the back of your eye with a special scanner, and measure the pressure inside your eye. Before treatment and one week after your third injection, you would also have a blood test. The entire process takes about three months from start to finish.
AI-generated summary from trial data ยท Jun 9, 2026 ยท Not medical advice
Iraq
Phase
Post-approval monitoring
Sponsor
Al-Mustansiriyah University
Collaborators
Baghdad Medical City
Enrollment target
~102 participants
Started
February 2025
Primary completion
December 2025
This trial's estimated completion date has passed โ the record may not be fully up to date.
Age range
40 Years and older
Last updated on clinicaltrials.gov in September 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.